经过验证的同行比较

NVO vs LLY

Novo Nordisk A/S与Eli Lilly and Company相比。本页面比较了两家经过来源验证的公司简介，并且没有引入未经验证的价格目标。

NVO

Novo Nordisk A/S

$189.43

LLY

$782.10

NVO: Pharmaceuticals

LLY: Pharmaceuticals

NVO: 诊断增加、治疗能力及报销改善可扩大肥胖治疗可及人群。灌装和原料药投资可改善供应并支持更广泛上市。口服及联合疗法可延展肥胖、糖尿病及相关疾病领域的领先地位。

LLY: 多头重点关注 obesity drug adoption and pipeline expansion。

NVO: 竞争对手的疗效、供应和定价可能压制糖尿病及肥胖领域份额和增长。支付方限制、政府谈判及可负担性担忧可能降低实际经济性。质量问题或复杂产能项目延迟可能在需求快速增长时限制供应。

LLY: 空头重点关注 supply constraints and valuation expectations。

Financial results for the first three months of 2026Novo Nordisk A/S · earnings已验证

已获取: 2026/7/12 UTC 0:00:00

已发表: 2026/5/6 00:00:00

Novo Nordisk A/S Investor RelationsNovo Nordisk A/S · company已验证

已获取: 2026/7/12 UTC 0:00:00

Novo Nordisk SEC filings and company factsU.S. Securities and Exchange Commission · filing已验证

已获取: 2026/7/12 UTC 0:00:00

已发表: 2026/5/6 00:00:00

Lilly Reports First-Quarter 2026 Financial ResultsEli Lilly and Company · earnings已验证

已获取: 2026/7/11 UTC 0:00:00

已发表: 2026/4/30 00:00:00

Eli Lilly Investor RelationsEli Lilly and Company · company已验证

已获取: 2026/7/11 UTC 0:00:00

Form 10-Q for the Quarter Ended March 31, 2026Eli Lilly and Company · filing已验证

已获取: 2026/7/11 UTC 0:00:00

已发表: 2026/4/30 00:00:00

LLY editorial research profileAlphaVue Research · editorial已验证

已获取: 2026/7/11 UTC 0:00:00